These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33743228)

  • 1. Gene therapy for spinal muscular atrophy: hope and caution.
    Goemans N
    Lancet Neurol; 2021 Apr; 20(4):251-252. PubMed ID: 33743228
    [No Abstract]   [Full Text] [Related]  

  • 2. Guidance on Gene Replacement Therapy in Spinal Muscular Atrophy: A Canadian Perspective.
    Oskoui M; Gonorazky H; McMillan HJ; Dowling JJ; Amin R; Gagnon C; Selby K
    Can J Neurol Sci; 2022 May; 49(3):398-401. PubMed ID: 34082851
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene replacement therapy for spinal muscular atrophy unmasking occult hepatitis C in a pediatric patient.
    Lakhotia A; Turek G; Green J; Khan M
    Muscle Nerve; 2022 Jan; 65(1):E2-E3. PubMed ID: 34644404
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic therapy for spinal muscular atrophy.
    MacKenzie A
    Nat Biotechnol; 2010 Mar; 28(3):235-7. PubMed ID: 20212484
    [No Abstract]   [Full Text] [Related]  

  • 5. Trans-splicing, more than meets the eye: multifaceted therapeutics for spinal muscular atrophy.
    Butchbach ME
    Hum Gene Ther; 2011 Feb; 22(2):121-5. PubMed ID: 21288085
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials.
    Zanetta C; Nizzardo M; Simone C; Monguzzi E; Bresolin N; Comi GP; Corti S
    Clin Ther; 2014 Jan; 36(1):128-40. PubMed ID: 24360800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of gene-corrected motor neurons as a therapeutic strategy for spinal muscular atrophy.
    Meyer K; Miranda CJ; Kaspar BK
    Mol Ther; 2013 Mar; 21(3):502-3. PubMed ID: 23449105
    [No Abstract]   [Full Text] [Related]  

  • 8. Augmenting the SMN Protein to Treat Infantile Spinal Muscular Atrophy.
    Kim JK; Monani UR
    Neuron; 2018 Mar; 97(5):1001-1003. PubMed ID: 29518354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spinal Muscular Atrophy and Common Therapeutic Advances.
    Bozorg Qomi S; Asghari A; Salmaninejad A; Mojarrad M
    Fetal Pediatr Pathol; 2019 Jun; 38(3):226-238. PubMed ID: 31060440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future avenues for therapy development for spinal muscular atrophy.
    Groen EJN
    Expert Opin Drug Discov; 2018 Oct; 13(10):899-902. PubMed ID: 30124076
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal Muscular Atrophy Type 1 With Exon 8 Deletion and Bilateral Optic Atrophy.
    Behera B; Kumar A
    Indian Pediatr; 2020 Dec; 57(12):1191. PubMed ID: 33318336
    [No Abstract]   [Full Text] [Related]  

  • 13. Sense in antisense therapy for spinal muscular atrophy.
    MacKenzie A
    N Engl J Med; 2012 Feb; 366(8):761-3. PubMed ID: 22356331
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances and challenges in developing a therapy for spinal muscular atrophy.
    Anderton RS; Mastaglia FL
    Expert Rev Neurother; 2015; 15(8):895-908. PubMed ID: 26200127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal muscular atrophy: recent advances and future prospects.
    Nicole S; Diaz CC; Frugier T; Melki J
    Muscle Nerve; 2002 Jul; 26(1):4-13. PubMed ID: 12115944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of muscle strength with a handheld dynamometer in patients with chronic spinal muscular atrophy.
    Febrer A; Rodriguez N; Alias L; Tizzano E
    J Rehabil Med; 2010 Mar; 42(3):228-31. PubMed ID: 20411217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More is needed to complement the available therapies of spinal muscular atrophy.
    Singh RN
    Future Med Chem; 2019 Nov; 11(22):2873-2876. PubMed ID: 31668092
    [No Abstract]   [Full Text] [Related]  

  • 18. Spinal muscular atrophies reveal motor neuron vulnerability to defects in ribonucleoprotein handling.
    Anderson K; Talbot K
    Curr Opin Neurol; 2003 Oct; 16(5):595-9. PubMed ID: 14501843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy.
    Valori CF; Ning K; Wyles M; Mead RJ; Grierson AJ; Shaw PJ; Azzouz M
    Sci Transl Med; 2010 Jun; 2(35):35ra42. PubMed ID: 20538619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zolgensma - one-time gene therapy for spinal muscular atrophy.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):113-114. PubMed ID: 31381549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.